Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Instil Bio Inc TIL

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.


NDAQ:TIL - Post by User

Bullboard Posts
Post by Giverbulletson Oct 25, 2011 9:55am
370 Views
Post# 19178636

QE3....not.

QE3....not.Interesting discussion about US liquidity and central banking. Doesn't look like we'll see any easing in the US anytime soon, but at the same time, it appears that they are pretty comfortable with where they are sitting. To me, stability and confidence is key when owning an equity like GPD who will make alot of money at these gold levels.

Another fellow from Barclay's was also just on BNN and he was very confident that the Euopean situation would get fixed appropriately, especially when 2008 is fresh in everyone's minds on what will happen if you don't fix the banks.


https://watch.bnn.ca/headline/october-2011/headline-october-24-2011/#clip555168

https://watch.bnn.ca/headline/october-2011/headline-october-24-2011/#clip555154


Ideally, if this can all blow over and the market regains confidence along with some continued chindia demand for gold, we will be extremely well positioned for the next year, or so......maybe more. Let's hope this all plays out nicely.


Giver.
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse